We can’t make your holiday shopping list any shorter, but we can make it less expensive. Now through December 18, we’ll be rolling out exclusive discount codes for GQ readers on our favorite no-brainer, they’re-sure-to-love-it gifts (all of which we also suggest picking up for yourself). These deals will only last a limited time each, and once they’re gone, they’re gone. Kicking things off: a whole $200 off the state-of-the-art, award-winning Hydrow rowing machine (just enter “GQ200” at checkout), which’ll help you carve out a Rob-Lowe-in-Oxford–Blues-esque body in no time flat. Check back here all month long as we announce new, never-seen-before markdowns on a slew of truly unmissable gear.
Save $200 on a Hydrow rowing machine with code “GQ200” (through Dec. 4)
We all began the quarantine with such high hopes for self-improvement, didn’t we? I’m going to use this time to eat better, work out more, get completely ripped! you declared in March. Now it’s December, and all that’s gotten ripped are the tops of several dozen Doritos bags as you work through season four of The Crown. But it’s not too late to turn this thing around: all you need is the right equipment, and we’ve scored you a stellar deal on exactly that.
The Hydrow is a cutting-edge rowing machine that uses advanced technology to strengthen your whole body—a whopping 86% of your muscles!—while delivering a silky smooth and peacefully quiet ride that really feels like you’re out on the water. Right now, in addition to the more than 1,500 workout classes you can access from the machine’s 22” touchscreen, Hydrow’s tossing in $200 worth of extra gear for free, including a heart rate monitor and wireless headphones. And, when you enter the code “GQ200” at checkout, you’ll save another $200 on top of that. So, yeah: no excuses left, people! If you order one of these bad boys now, you should be well on your way to fitness god status by the time the vaccine arrives.
Dr. Adrienne Lara joins exclusive Haute Beauty Network as a Women’s Sexual Medicine expert representing the Los Angeles market.
OXNARD, Calif. (PRWEB) December 01, 2020
At Celebrating Women Center in Oxnard, California, Dr. Adrienne Lara, MD, wants her patients to know that she went to medical school for you. She believes good patient care is collaborative and involves both the patient and doctor working together as a team to get to the same goal — patient wellness. Dr. Lara takes the time to listen to her patients to better understand who they are, so she’s not treating symptoms, but the whole patient, including their mind, body, and spirit.
Voted favorite MedSpa by the Ventura County Reporter and Best Med Spa Readers’ Choice County Star 2018, Celebrating Women Center offers a number of health and wellness treatments focused on regenerative medicine that allows patients’ natural beauty to shine through, including micro-needling, platelet-rich plasma (PRP), and vaginal rejuvenation with advanced medical treatments such as laser therapy and surgical procedures.
After beginning her career in health care as a nurse, Dr. Lara then went to medical school at Boston University School of Medicine and completed her internship and residency program in obstetrics and gynecology at Beth Israel Deaconess Medical Center, which is part of Harvard Medical School.
Dr. Lara takes great pride in her community and believes as a doctor it’s her role to teach and share her knowledge so that her patients understand that they have options. Her integrity and authenticity when it comes to health care are why she’s so loved by all who see her.
Dr. Lara is fluent in English and Spanish to serve patients from a variety of backgrounds.
Learn more about Dr. Adrienne Lara by visiting: https://hauteliving.com/hautebeauty/member/dr-adrienne-lara/
ABOUT HAUTE BEAUTY NETWORK:
Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
For the original version on PRWeb visit: https://www.prweb.com/releases/women_s_sexual_medicine_expert_dr_adrienne_lara_joins_exclusive_haute_beauty_network/prweb17528982.htm
Sport Medicine Market Exclusive Profitable Comprehensive Report Cover COVID-19 Updates | Smith & Nephew plc, Stryker Corporation
The MarketWatch News Department was not involved in the creation of this content.
Nov 24, 2020 (WiredRelease via Comtex) —
A consciously conceived and designed business intelligence report titled Global Sport Medicine market 2020 by Manufacturers, Type, and Application, Forecast to 2029 by MarketResearch.biz discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Sport Medicine market which is marking on the enlargement and opening doors for outlook growth in the coming years.
This is the latest report, covering the current COVID-19/Corona Virus pandemic impact on the market which has affected every aspect of life globally. This has brought along several changes in market conditions and the Business areas. The rapidly changing market scenario and initial and future assessment of the impact are covered in the Sport Medicine market report.
For All-Inclusive Information: Download a FREE sample copy of Sport Medicine Market Report Study 2020-2029 at https://marketresearch.biz/report/sport-medicine-market/request-sample
(Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, list of tables and figures, Impact Analysis of COVID-19, TOC, an outlook to key players of the market and comprising key regions.)
The major companies are exceedingly focused on innovation in Sport Medicine production technology to enhance ledge life and efficiency. The best long-term development path for Sport Medicine market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.
Key manufacturers are included based on the company profile, sales data and product specifications, etc: Smith & Nephew plc, Stryker Corporation, Johnson & Johnson Private Limited, Arthrex Inc., Conmed Corporation, Zimmer Biomet Holdings, Inc., Breg, Inc., Mueller Sports Medicine, Inc., DJO Global, Inc., Wright, Medical Group N.V.
Each manufacturer or Sport Medicine market player’s growth rate, gross profit margin, and revenue figures is provided in a tabular, simple format for few years and an individual section on Sport Medicine market recent development such as collaboration, mergers, acquisition, and any new service or new product launching in the market is offered.
Sport Medicine Market Segmentation Outlook By product, application, and region:
Global sport medicine market segmentation, by product:
Body Reconstruction and Repair Products
Body Support and Recovery Product
Body Monitoring and Evaluation
Global sport medicine market segmentation, by application:
Ankle & Foot Injuries
Back & Spine Injuries
Elbow & Wrist Injuries
Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Sport Medicine Market: https://marketresearch.biz/report/sport-medicine-market/covid-19-impact
Regional Analysis:On the idea of geography, the Sport Medicine Market report covers statistics for a couple of geographies inclusive of, North America (U.S., Mexico, Canada) South America (Argentina, Brazil) The Middle East & Africa (South Africa, Saudi Arabia) Asia-Pacific (China, Japan, India, Southeast Asia) Europe (U.K., Spain, Italy, Germany, France, Russia)
In addition, The following years considered for this study to forecast the global Sport Medicine market size are
Nautilus Group, Inc. (The) (NYSE:NLS), lululemon athletica inc. (NASDAQ:LULU) – Exclusive: Nautilus CEO On Fitness During COVID-19, The Company’s Answer To Peloton
Nautilus Inc (NYSE: NLS) CEO Jim Barr chatted with Benzinga’s PreMarket Prep team to discuss the turnaround of the company, what’s next in the connected fitness world and why the stock is still attractive after a 1,000% increase in 2020.
Nautilus Mounts Turnaround During Pandemic: The CEO discussed the turnaround he helped steer since taking over the company in July.
Nautilus just reported its “most profitable quarter in its 40-year history,” Barr said.
Barr joined Nautilus from Ritchie Bros, where he helped the 60-year-old company with its digital transformation.
“I came here because this is a great company with fantastic brands and a broad portfolio of different types of products at different price points.”
A survey done by Nautilus showed that between 12% and 30% of respondents will never go back to the gym, while others said they would only go back to gym with a vaccine. Some will balance a gym membership with at-home fitness.
The gym membership market is worth $40 billion compared to the $3.6-billion at-home fitness market, Barr said, adding tha tthis could change over time.
Nautilus saw seven times more new customers in the recently reported quarter than the prior year, which he sid could lead to long-term growth.
Competing With Peloton: Nautilus was late to the connected fitness game, Barr said: “We missed some trends in market.”
The company had to accelerate the portfolio after realizing it didn’t have a replacement for its Max Trainer, he said — and the company wasn’t digital enough.
The first Bowflex bike launched by Nautilus is half the price point of Peloton Interactive (NASDAQ: PTON) offerings and allows an open software platform, which are key differentiators, Barr said.
Nautilus recently launched the VeloCore bike under the Bowflex brand. “We think we have a real winner here,” the CEO said.
The VeloCore bike is the first “unstationary” bike that can lean from side to side and offers a better core and arm workout than competitive products.
Nautilus’ digital membership platform Journey offers trainer-led on-demand videos and adaptive workouts.
People can watch Netflix (NASDAQ: NFLX) or other streaming apps in the background while being coached or working out.
Barr pointed to the “combination of the differentiated product and connected fitness” as being a game-changer for the VeloCore.
Nautilus Stock Performance, Valuation: Barr said the timing of the Nautilus earnings announcement on Monday with Pfizer’s vaccine news was bad news for the stock.
“Those two things happening the same day didn’t help our stock.”
Shares of Nautilus are up over 1,000% in 2020.
Barr pointed to Mirror selling to Lululemon Athletica (NASDAQ: LULU) for around 5x sales. Peloton also has a higher price-to-sales ratio than Nautilus, Barr said.
“Those valuations are fantastic.”
Watch the full interview with Jim Barr in the clip below, or listen to the podcast here
PreMarket Prep is a daily trading show hosted by prop trader Dennis Dick and former floor trader Joel Elconin. You can watch PreMarket Prep live every day from 8-9 a.m. ET Benzinga’s
NEW YORK, Oct. 21, 2020 /PRNewswire/ — sbe, the leading international hospitality group that develops, manages and operates award-winning brands, today announced a multi-faceted global partnership with leading luxury wellness and lifestyle brand, DOGPOUND. The initial rollout will commence on October 21st, 2020 and will be highlighted by the launching of a customized fitness program at renowned sbe properties SLS South Beach and SLS Brickell. This will be closely followed by the addition of Mondrian Doha and other sbe properties as the partnership expands internationally.
A favorite among celebrities and supermodels from around the world, this will be the first hotel partnership for DOGPOUND, providing sbe guests with exclusive access to a dynamic array of virtual training sessions, previously only available to DOGPOUND clients. In the initial launch phase, DOGPOUND’s expert fitness trainers will coach sbe guests through virtual one-on-one fitness training sessions in the comfort of their sbe hotel rooms. Tailored to each guest’s fitness level and equipment access, the DOGPOUND trainers offer a bespoke approach to training that will include key stretches, bodyweight moves, and an overall, well-rounded fitness experience.
“We’ve noticed a significant rise in requests for health and wellness services at sbe properties and sought out a partner that aligned with our consumer’s luxury lifestyle and could provide the best-of-the-best,” said sbe Chief Business Officer Philippe Zrihen. “DOGPOUND has a cult following as one of the most innovative and trendsetting companies in the lifestyle fitness space. As our guests look for new ways to stay healthy, this partnership provides them with remarkable, results-driven personal training and a wellness-focused community at the touch of a button.”
In the coming year, sbe and DOGPOUND will expand the virtual workout program to additional properties with potential for even more unique fitness opportunities or additional avenues of collaboration.
“This is a first for our company and we jumped at the chance to bring our private training sessions and nutritional programs to global travelers through a partnership with sbe, a luxury brand we’ve long admired,” says DOGPOUND Founder and CEO, Kirk Myers. “Since each workout is catered to the individual, no session is the same, meaning sbe guests can return to their hotel room day after day, week after week, for a completely new experience. We’re providing access to some of DOGPOUND’s top trainers so sbe guests can CRUSH IT from anywhere in the world.”
sbe’s collaboration with DOGPOUND further advances the hospitality group’s health and wellness platform in response to growing interests among lifestyle consumers – 80 percent of whom are more engaged with their health than they were prior to the pandemic, according to a recent survey by Slingshot. Providing a full-service approach to wellness, sbe already partners with leading fitness companies Therabody to provide deep muscle therapy amenities, and Goldsheep for branded activewear, with more collaborations expected to be announced.
“Wellness is no longer a nice-to-have when guests are picking their preferred hotel, it is a must-have. DOGPOUND is a natural complement
Primo Nutraceuticals Inc. signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada
COVID-19 Test Kits
COVID-19 Test Kits
VANCOUVER, British Columbia, Oct. 21, 2020 (GLOBE NEWSWIRE) — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) announces the signing of a Memorandum of Understanding (MOU) with Neo-Nostics ™ (Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China (“Neo-Nostics”) as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics ™ 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).
The Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020. Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.
The Neo-Nostics ™ 2019-nCoV IgG/IgM Rapid Testing Kit is currently registered with the FDA. Primo will be submitting the application for approval to Health Canada immediately. Neo-Nostics ™ has committed to supporting Primo’s efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and clinical studies concerning the Test Kits.
Follow the link for a video demonstration: http://www.neo-nostics.com/skin/images/mp40.mp4
About the Neo-Nostics ™ Rapid Test Kits
The Neo-Nostics ™ 2019-nCoV Antibody Detection Reagent Kit (Colloidal Gold Method) has the advantage of rapidity, convenience, high accuracy, and can make up for the shortcomings of professional requirements, time consumption and low positive detection rate of PCR nucleic acid detection, and can be used as an important supplementary detection method for the diagnosis of coronal pneumonia.
Through detection and calculation, it is found that the comprehensive accuracy rate of the Neo-Nostics ™ 2019-nCoV IgM Detection Reagent is higher than 95%.
During the worst period of the epidemic in China, the reagent kit was donated to hospitals and the CDC in the most severely infected areas of Hubei for clinical auxiliary diagnosis. At present, the verification reports made by three clinical units prove that the positive detection rate of clinically confirmed cases has reached 92%, which has exceeded the general detection effect. Not only negative or positive results can be detected, but also the early, middle and or recovery period of virus infection can be distinguished by the positive strength of IgM or IgG.
Source: Clinical study report conducted by the Institute of Virology, in the capital city of Hubei, China and The Chinese Academy of Sciences in Beijing, China.
DISCLAIMER: “The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time”.
Clinical Applications of Reagents
This reagent has been used by professionals in China since February 2020 in an area that was the hardest hit and impacted most severely by COVID-19, in the form of clinical auxiliary diagnosis.
The reagent kit was clinically verified by several professionals, hospitals, and universities respectively, and
Exclusive: AstraZeneca U.S. COVID-19 Vaccine Trial May Resume as Soon as This Week – Sources | Top News
By Julie Steenhuysen and Marisa Taylor
CHICAGO/WASHINGTON (Reuters) – AstraZeneca Plc’s COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness, four sources told Reuters.
AstraZeneca’s large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company’s UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.
The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said.
The FDA did not respond to a request for comment.
The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources.
UK regulatory officials previously reviewed the illness and determined there was “insufficient evidence to say for certain” that it was or was not related to the vaccine. It permitted the trial to resume enrolling participants in the UK, according to a draft of the updated consent form shared with Reuters.
“In this case, after considering the information, the independent reviewers and MHRA (Medicines and Healthcare products Regulatory Agency) recommended that vaccinations should continue,” the draft consent form stated. “Close monitoring of the affected individual and other participants will be continued.”
Regulators in Brazil, India and South Africa also previously allowed AstraZeneca to resume its vaccine trials there.
Responding to a request, British regulators shared with Reuters a draft of a form letter to UK vaccine trial participants, dated Oct. 14 and signed by the Oxford COVID-19 Vaccine Team. It says the U.S. FDA had “completed their analysis” and said vaccination in the United States would resume shortly.
FDA “has come to the same conclusion as the other drug regulators including the MHRA,” the letter states. The regulator, Health Research Authority, did not say if the letter had been sent or immediately respond to questions about it.
An AstraZeneca spokeswoman said the communication is not from the company and it “cannot verify the content,” referring to the draft letter to patients.
“We also cannot comment on a pending FDA decision,” she said.
(Reporting by Julie Steenhuysen and Marisa Taylor; Editing by Bill Berkrot)
Copyright 2020 Thomson Reuters.